



Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.6	09.04.2021	26486-00016	Date of first issue: 29.10.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Ezetimibe / Atorvastatin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-	:	Pharmaceutical
stance/Mixture		

1.3 Details of the supplier of the safety data sheet

Company	:	Organon & Co. Shotton Lane NE23 3JU Cramlington NU - Great Britain
Telephone	:	44 1 670 59 30 00
E-mail address of person responsible for the SDS	:	EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Specific target organ toxicity - repeated exposure, Category 2 Long-term (chronic) aquatic hazard, Category 2 H373: May cause damage to organs through prolonged or repeated exposure. H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)						
Hazard pictograms	:					
Signal word	:	Warning				
Hazard statements	:	H373 May cause damage to organs through prolonged or repeated exposure.H411 Toxic to aquatic life with long lasting effects.				
Precautionary statements	:	Prevention:P260Do not breathe dust.P273Avoid release to the environment.				

according to Regulation (EC) No. 1907/2006



Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.6	09.04.2021	26486-00016	Date of first issue: 29.10.2014

Response:

P314 Get medical advice/ attention if you feel unwell.

P391 Collect spillage.

Hazardous components which must be listed on the label:

Atorvastatin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No.	Classification	Concentration (% w/w)
Atorvastatin	Registration number 134523-03-8	STOT RE 2; H373 (Liver, muscle) Aquatic Chronic 2; H411	>= 10 - < 20
Ezetimibe	163222-33-1	Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 1	>= 2.5 - < 10

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.

according to Regulation (EC) No. 1907/2006



Version 2.6	Revision Date: 09.04.2021		0S Number: 486-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014			
In cas	e of skin contact	:	Wash with water a Get medical atten	and soap. tion if symptoms occur.			
In case of eye contact			: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.				
lf swa	llowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.				
4.2 Most i	mportant symptoms ar	nd e	effects, both acute	and delayed			
Risks		:	May cause dama exposure.	ge to organs through prolonged or repeated			
			the skin.	can cause mechanical irritation or drying of			
			Dust contact with	the eyes can lead to mechanical irritation.			
4.3 Indicat	tion of any immediate	med	dical attention and	I special treatment needed			
Treatr	ment	:	Treat symptomati	cally and supportively.			
5.1 Exting	I 5: Firefighting meas uishing media	sur					
5 .1 Exting Suitab	uishing media ble extinguishing media	sur :	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical				
5 .1 Exting Suitab	uishing media ble extinguishing media table extinguishing	sur :	Water spray Alcohol-resistant Carbon dioxide (C				
5 .1 Exting Suitab Unsui ^r media	uishing media ble extinguishing media table extinguishing	:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical None known.	:02)			
5.1 Exting Suitab Unsui media 5.2 Specia	uishing media ole extinguishing media table extinguishing I hazards arising from fic hazards during fire-	:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical None known. e substance or mi Avoid generating concentrations, an potential dust exp	xture dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a			
5.1 Exting Suitab Unsuir media 5.2 Specia Specia fightin	uishing media ole extinguishing media table extinguishing I hazards arising from fic hazards during fire-	:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical None known. e substance or mi Avoid generating concentrations, an potential dust exp	xture dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a losion hazard. bustion products may be a hazard to health.			
 5.1 Exting Suitab Unsuir media 5.2 Specia Specia fightin Hazar ucts 	uishing media ole extinguishing media table extinguishing I hazards arising from fic hazards during fire-	:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical None known. substance or mi Avoid generating concentrations, an potential dust exp Exposure to comb Carbon oxides Nitrogen oxides (I Fluorine compour	xture dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a losion hazard. bustion products may be a hazard to health.			
 5.1 Exting Suitat Unsuir media 5.2 Specia Specia fightin Hazar ucts 5.3 Advice Specia 	uishing media ole extinguishing media table extinguishing al hazards arising from fic hazards during fire- g	: the :	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical None known. substance or mi Avoid generating concentrations, al potential dust exp Exposure to comb Carbon oxides Nitrogen oxides (I Fluorine compour Metal oxides	xture dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a losion hazard. bustion products may be a hazard to health.			

according to Regulation (EC) No. 1907/2006



Ezetimibe / Atorvastatin Formulation

Version 2.6	Revision Date: 09.04.2021	SDS Number: 26486-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
			ray to cool unopened containers. amaged containers from fire area if it is safe to do a.
SECTION	N 6: Accidental relea	se measures	
6.1 Perso	nal precautions, prote	ctive equipment a	nd emergency procedures
Perso	onal precautions	Follow safe h	protective equipment. andling advice (see section 7) and personal pro- nent recommendations (see section 8).
6.2 Enviro	onmental precautions		
Envir	onmental precautions	Prevent furth Retain and di	e to the environment. er leakage or spillage if safe to do so. spose of contaminated wash water. ies should be advised if significant spillages ntained.
6.3 Metho	ds and material for co	ontainment and cle	aning up
Meth	ods for cleaning up	tainer for disp Avoid dispers with compres Dust deposits es, as these r leased into th Local or natio posal of this r employed in t mine which re Sections 13 a	al of dust in the air (i.e., clearing dust surfaces

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion.
		Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Do not breathe dust.
		Do not swallow.
		Avoid contact with eyes.
		Avoid prolonged or repeated contact with skin.
		Handle in accordance with good industrial hygiene and safety

according to Regulation (EC) No. 1907/2006



Ezetimibe / Atorvastatin Formulation

Ver 2.6	sion	Revision Date: 09.04.2021		DS Number: 3486-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
	Hygien	e measures	:	 practice, based on the results of the workplace exposure a sessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to environment. If exposure to chemical is likely during typical use, provide flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash containated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. 	
7.2	Conditi	ons for safe storage,	inc	luding any incom	patibilities
	Requirements for storage areas and containers		:	Keep in properly the particular nati	abelled containers. Store in accordance with onal regulations.
	Advice	on common storage	:	Do not store with Strong oxidizing a	the following product types: agents
7.3	-	c end use(s) c use(s)	:	No data available	

SECTION 8: Exposure controls/personal protection

8.1 Control parameters


Occupational Exposure Limits

O a man a manta			O e esta el la calcala este se	Deele
Components	CAS-No.	Value type (Form	Control parameters	Basis
		of exposure)		
Cellulose	9004-34-6	TWA (inhalable	10 mg/m3	GB EH40
		dust)		
	Further inform	ation: For the purpo	ses of these limits, respirable	e dust and in-
	halable dust a	re those fractions of	airborne dust which will be c	ollected when
	sampling is ur	ndertaken in accorda	nce with the methods descri	bed in
	MDHS14/4 Ge	eneral methods for s	ampling and gravimetric ana	ysis or respira-
	ble, thoracic a	nd inhalable aerosol	s., The COSHH definition of	a substance
	hazardous to	health includes dust	of any kind when present at	a concentration
	in air equal to	or greater than 10 m	ng.m-3 8-hour TWA of inhala	ble dust or 4
	mg.m-3 8-hou	r TWA of respirable	dust. This means that any du	ust will be sub-
	ject to COSHI	l if people are expos	ed to dust above these level	s. Some dusts
	have been as	signed specific WEL	s and exposure to these mus	t comply with
	the appropriat	e limits., Most indust	trial dusts contain particles of	a wide range
			n and fate of any particular p	
			stem, and the body respons	
			he particle. HSE distinguishe	
			termed 'inhalable' and 'respi	

according to Regulation (EC) No. 1907/2006



rsion S	Revision Date: 09.04.2021	SDS Number: 26486-00016		ate of last issue: 16.10.20 ate of first issue: 29.10.20	
	and resp to th mat thei Furt hala sam MDI ble, haz in a	mouth during breathin biratory tract. Respirab ne gas exchange regio erial are given in MDH r own assigned WEL, a TWA (Resp dust) her information: For the ble dust are those fract opling is undertaken in HS14/4 General metho thoracic and inhalable ardous to health include r equal to or greater th	g and is le dust a n of the S14/4., all the re birable e purpo ctions of accorda ods for s aeroso les dust	on of airborne material th s therefore available for de approximates to the fraction lung. Fuller definitions ar Where dusts contain com elevant limits should be con 4 mg/m3 ses of these limits, respir airborne dust which will hance with the methods de ampling and gravimetric a ls., The COSHH definition of any kind when presen- ng.m-3 8-hour TWA of inh dust. This means that an	eposition in the on that penetrates ad explanatory aponents that have omplied with. GB EH40 able dust and in- be collected when scribed in analysis or respira n of a substance t at a concentration nalable dust or 4
	ject have the of si entr dep frac ble and resp to th mat	to COSHH if people a e been assigned speci appropriate limits., Mo izes. The behaviour, d y into the human respi end on the nature and tions for limit-setting p dust approximates to t mouth during breathir piratory tract. Respirab he gas exchange regio erial are given in MDH r own assigned WEL, a	re exposi fic WEL st indus epositio ratory s size of urposes he fracti ig and is le dust a n of the S14/4., all the re	sed to dust above these less and exposure to these less and exposure to these less and exposure to these less and fate of any particular ystem, and the body respected by the particle. HSE distinguitermed 'inhalable' and 'respected by the respected by the therefore available for deapproximates to the fractional fung. Fuller definitions ar Where dusts contain complevant limits should be contained by the total by the termed by termed	evels. Some dusts must comply with es of a wide range ar particle after onse that it elicits, hishes two size espirable'., Inhala- at enters the nose eposition in the on that penetrates ad explanatory oponents that have complied with.
	hala sam MDI ble, haz in ai	ble dust are those fractional fractional to the second sec	e purpo ctions of accorda ods for s aeroso les dust aan 10 r	20 mg/m3 ses of these limits, respir airborne dust which will l ance with the methods de ampling and gravimetric ls., The COSHH definition of any kind when presen ng.m-3 8-hour TWA of inh dust. This means that an	be collected when scribed in analysis or respira n of a substance t at a concentration nalable dust or 4
	ject have the of si entr dep frac ble and resp to th mat	to COSHH if people a e been assigned speci appropriate limits., Mo izes. The behaviour, d y into the human respi end on the nature and tions for limit-setting p dust approximates to t mouth during breathin piratory tract. Respirab ne gas exchange regio erial are given in MDH	re exposi- fic WEL st indus epositio ratory s size of urposes he fract g and is le dust a n of the S14/4.,	sed to dust above these less and exposure to these less and exposure to these levels and fate of any particular ystem, and the body respected by the particle. HSE distinguitermed 'inhalable' and 'rection of airborne material the stherefore available for deapproximates to the fractional fung. Fuller definitions ar Where dusts contain complevant limits should be contained by the statement of the	evels. Some dusts must comply with as of a wide range ar particle after onse that it elicits ishes two size espirable'., Inhala- at enters the nose eposition in the on that penetrates ad explanatory aponents that have
Atorva	statin 134 8	523-03- TWA		0.05 mg/m3 (OEB 3)	Internal





Ezetimibe / Atorvastatin Formulation

Version 2.6	Revision Da 09.04.2021		Number: 86-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014	
Ezeti	mibe	163222-33- 1	Wipe limit TWA	0.5 mg/100 cm ² 25 μg/m3 (OEB 3)	Internal Internal
			Wipe limit	250 µg/100 cm ²	Internal

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Remarks Skin and body protection	:	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis- posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to BS EN 143
Filter type	·	Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance Colour Odour Odour Threshold	:	powder off-white No data available No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available

according to Regulation (EC) No. 1907/2006



Ezetimibe / Atorvastatin Formulation

Ver 2.6	sion	Revision Date: 09.04.2021		S Number: 186-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
	Flash p	point	:	Not applicable	
	Evapor	ation rate	:	No data available	9
	Flamm	ability (solid, gas)	:	May form explosi dling or other me	ive dust-air mixture during processing, han- ans.
	Flamm	ability (liquids)	:	No data available	9
	Upper explosion limit / Upper flammability limit		:	No data available	9
		explosion limit / Lower ability limit	:	No data available	9
	Vapour	pressure	:	No data available	9
	Relativ	e vapour density	:	No data available	9
	Relativ	e density	:	No data available	9
	Density	/	:	No data available	9
	Partitio octano	er solubility n coefficient: n-	:	0.01 g/l No data available No data available	
	_	position temperature	:	No data available	9
	Viscosi Visc	ty cosity, kinematic	:	No data available	9
	Explos	ive properties	:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
9.2	Molecu	nformation llar weight	:	No data available	
	Particle	e size	:	No data available	9

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

according to Regulation (EC) No. 1907/2006



Ezetimibe / Atorvastatin Formulation

Versi 2.6	on	Revision Date: 09.04.2021		S Number: 486-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014		
I	Hazard	ous reactions	:	dling or other me	May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.		
10.4	Condit	ions to avoid					
(Conditi	ons to avoid	:	Heat, flames and Avoid dust forma			
10.5	Incom	patible materials					
		als to avoid	:	Oxidizing agents			
10.6	Hazaro	lous decomposition	orod	lucts			
I	No haz	ardous decomposition	prod	ducts are known.			
SEC	TION	11: Toxicological in	for	mation			
11.1	Inform	ation on toxicologica	l eff	ects			
		ation on likely routes of		Inhalation			
(exposu	re		Skin contact			
				Ingestion Eye contact			
	Acute	toxicity		,			
		ssified based on availa	ble	information.			
<u>(</u>	Compo	onents:					
	Atorva	statin:					
	Acute o	oral toxicity	:	LD50 (Rat, male a	and female): > 5,000 mg/kg		
				LD50 (Mouse, ma	ale and female): > 5,000 mg/kg		
	Ezetim	ibe:					
		oral toxicity	:	LD50 (Rat): > 5,0	00 mg/kg		
				LD50 (Mouse): >	5,000 mg/kg		
				LD50 (Dog): > 3,0)00 mg/kg		
1	Acute i	nhalation toxicity	:	Remarks: No data	a available		
1	Acute o	dermal toxicity	:	Remarks: No data	a available		
		oxicity (other routes of stration)	:	LD50 (Rat): > 2,0 Application Route			
				LD50 (Mouse): > Application Route	1,000 - < 2,000 mg/kg : Intraperitoneal		

Skin corrosion/irritation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006



Ezetimibe / Atorvastatin Formulation

sion	Revision Date: 09.04.2021	SDS Number: 26486-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
<u>Comp</u>	oonents:		
Atorv	astatin:		
Speci		: Rabbit	
Resul	t	: No skin irritation	
Ezetir	nibe:		
Speci		: Rabbit	
Resul	t	: No skin irritation	
Serio	us eye damage/eye	rritation	
	assified based on av	ilable information.	
<u>Comp</u>	oonents:		
	astatin:		
Speci		: Rabbit	
Metho Resul		: Draize Test : No eye irritation	
i vesui	·		
Ezetir			
Speci Resul		: Rabbit	
Resul	L .	: No eye irritation	
Respi	iratory or skin sens	tisation	
-	sensitisation		
Not cl	assified based on av	ilable information.	
Resp	iratory sensitisation		
Not cl	assified based on av	ilable information.	
Comp	oonents:		
Atorv	astatin:		
Test 7		: Maximisation Tes	t
	sure routes	: Skin contact	
Speci Resul		: Guinea pig : negative	
Ezetin			
Test T		: Maximisation Tes	
Speci Resul		: Guinea pig : negative	
Resul	ι	. negative	
	cell mutagenicity	linkin inferencei i	
	assified based on av	ulable information.	
Comp	oonents:		

Atorvastatin:

according to Regulation (EC) No. 1907/2006



Vers 2.6	sion	Revision Date: 09.04.2021	-	S Number: 486-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
	Genoto	oxicity in vitro	:	Test Type: reverse Test system: Salm Result: negative	e mutation assay nonella typhimurium
				Test Type: reverse Test system: Esch Result: negative	
					mammalian cell gene mutation test ese hamster lung cells
					chromatid exchange assay ese hamster lung cells
	Genoto	oxicity in vivo	:	Test Type: In vivo Species: Mouse Cell type: Bone m Application Route Result: negative	
	Ezetim	ibe:			
		oxicity in vitro	:		ial reverse mutation assay (AMES) on: with and without metabolic activation
				Test Type: Chrom Test system: Hum Result: negative	osomal aberration an lymphocytes
	Genoto	oxicity in vivo	:	Test Type: Micron Species: Mouse Cell type: Bone m Application Route Result: negative	arrow
		ogenicity			
		ssified based on availa	able	information.	
		onents:			
	Exposu NOAEI LOAEL Result Target	s ation Route ure time - Organs		Mouse, male and oral (gavage) 2 Years 200 mg/kg body w 400 mg/kg body w negative Liver	veight
	Specie Applica	s ation Route	:	Rat, female oral (gavage)	

according to Regulation (EC) No. 1907/2006



Vers 2.6	sion	Revision Date: 09.04.2021		DS Number: 486-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
	LOAEL	ure time - Organs	: :	2 Years 100 mg/kg body v Musculo-skeletal	
	Ezetim	nibe:			
		ation Route ure time	: :	Rat, female oral (feed) 104 weeks negative	
		ation Route ure time	: : :	Rat, male oral (feed) 104 weeks negative	
		ation Route ure time	: : :	Mouse oral (feed) 104 weeks negative	
	Not cla	ductive toxicity Issified based on avail onents:	able	information.	
	Atorva	astatin:			
	Effects	on fertility	:	Species: Rat, fem	225 mg/kg body weight
				Species: Rat, ma	175 mg/kg body weight
	Effects ment	on foetal develop-	:	Result: No terato	ale oxicity: NOAEL: 20 mg/kg body weight genic effects, Embryo-foetal toxicity al toxicity observed.
				Species: Rabbit, Application Route Developmental To Result: No embry	: Oral oxicity: NOAEL: 100 mg/kg body weight
	Ezetim	nibe:			
		on fertility	:	Species: Rat, ma Fertility: NOAEL:	y/early embryonic development le and female > 1,000 mg/kg body weight s on fertility, No fetotoxicity

according to Regulation (EC) No. 1907/2006



Ezetimibe / Atorvastatin Formulation

Version 2.6	Revision Date: 09.04.2021	SDS Number: 26486-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
Effects ment	s on foetal develop-	: Test Type: Devel Species: Rat Application Route Developmental T Result: No advers	e: Oral oxicity: NOAEL: > 1,000 mg/kg body weight
		Test Type: Devel Species: Rabbit Application Route Developmental T Result: No advers	e: Oral oxicity: NOAEL: > 1,000 mg/kg body weight
STOT	- single exposure		

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Atorvastatin:

Exposure routes	:	Ingestion
Target Organs	:	Liver, muscle
Assessment	:	May cause damage to organs through prolonged or repeated
		exposure.

Repeated dose toxicity

Components:

Atorvastatin:

Species LOAEL Application Route Exposure time Target Organs	:	Rat, male and female 70 mg/kg oral (gavage) 52 Weeks Liver
Species LOAEL Application Route Exposure time Target Organs	:	Dog 10 mg/kg oral (gavage) 104 Weeks Liver
Ezetimibe: Species NOAEL Application Route Exposure time Remarks	:	Dog 1,000 mg/kg Oral 90 d No significant adverse effects were reported
Species NOAEL Application Route	:	Rat 1,500 mg/kg Oral

according to Regulation (EC) No. 1907/2006



ersion 6	Revision Date: 09.04.2021	SDS Number: 26486-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
Exposure time Remarks		: 90 d : No significa	nt adverse effects were reported
Spec	ies	: Mouse	
NOA		: 500 mg/kg	
	cation Route	: Oral	
	sure time	: 90 d	
Rema	arks	: No significa	nt adverse effects were reported
Spec		: Dog	
NOAI		: 300 mg/kg	
	cation Route	: Oral	
Expo: Rema	sure time	: 1 yr	nt adverse effects were reported
		. No olginiloa	
-	ration toxicity lassified based on ava	allable information	
	ponents:		
	mibe:		
	pplicable		
Expe	rience with human e	xposure	
Com	ponents:		
Atory	vastatin:		
Inges	tion		muscle pain, Fatigue, stomach discomfort, Ab- n, constipation, flatulence, liver function change
Ezeti	mibe:		
Inges	tion		Headache, Nausea, Vomiting, Diarrhoea, flatu- le pain, upper respiratory tract infection, Back ain
	12: Ecological in	formation	
.1 Toxic	city		
Com	ponents:		
	vastatin:		
			pholog promotos (fotbacd missour)) - 00
I OXIC	ity to fish	. LCOU (PIME	phales promelas (fathead minnow)): > 92 mg/l

	•	Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 200 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): 108 mg/l

according to Regulation (EC) No. 1907/2006



Vers 2.6	sion	Revision Date: 09.04.2021		S Number: 486-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014	
				Exposure time: 72 Method: OECD Te		
				NOEC (Pseudokir mg/l Exposure time: 72 Method: OECD Te		
	Toxicity	to microorganisms	:	EC50 : > 1,000 m Exposure time: 3 Test Type: Respir	ĥ	
	Toxicity to fish (Chronic tox- icity)		:	NOEC: 0.49 mg/l Exposure time: 33 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210		
		to daphnia and other invertebrates (Chron- ty)	:	NOEC: 0.2 mg/l Exposure time: 21 Species: Daphnia Method: OECD Te	magna (Water flea)	
	Ezetimi	ibe:				
	Toxicity	to fish	:	Exposure time: 96 Method: OECD Te		
		to daphnia and other invertebrates	:	Exposure time: 48 Method: OECD Te		
	Toxicity plants	to algae/aquatic	:	0.317 mg/l Exposure time: 96 Method: OECD Te		
				mg/l Exposure time: 96 Method: OECD Te		
	Toxicity	to microorganisms	:	EC50 : > 4.4 mg/l Exposure time: 3 Test Type: Respir Method: OECD Te Remarks: No toxic	ation inhibition	
				NOEC : 4.4 mg/l Exposure time: 3	h	

according to Regulation (EC) No. 1907/2006



Vers 2.6	sion	Revision Date: 09.04.2021		DS Number: 486-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
					ration inhibition est Guideline 209 city at the limit of solubility
	Toxicity icity)	/ to fish (Chronic tox-	:		
					d don variegatus (sheepshead minnow) city at the limit of solubility
		/ to daphnia and other invertebrates (Chron- ity)			
	M-Fact toxicity	or (Chronic aquatic)	:	1	
12.2		, tence and degradabil	ity		
	Compo	onents:			
	Atorva	statin:			
	Biodeg	radability	:	Result: Not readil Biodegradation: Exposure time: 2 Method: OECD T	7.7 %
	Ezetim	ibe:			
	Biodeg	radability	:	Result: Not readil Biodegradation: Exposure time: 2	6.8 %
	Stabilit	y in water	:	Hydrolysis: 50 % Method: OECD T	4.5 d) est Guideline 111
12.3	Bioaco	cumulative potential			
	<u>Compo</u>	onents:			
	Atorva	statin:			
	Partitio octano	n coefficient: n- I/water	:	log Pow: 1.62	
	Ezetim	ibe:			
	Bioacc	umulation	:	Exposure time: 9 Bioconcentration	s macrochirus (Bluegill sunfish) 7 d factor (BCF): 173 est Guideline 305

according to Regulation (EC) No. 1907/2006



Ezetimibe / Atorvastatin Formulation

Version 2.6	Revision Date: 09.04.2021	-	DS Number: 6486-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014	
	ion coefficient: n- Iol/water	:	log Pow: 4.36		
12.4 Mobi	ility in soil				
Com	ponents:				
Atory	/astatin:				
	bution among environ- al compartments	:	log Koc: 2.84		
Ezeti	mibe:				
	bution among environ- al compartments	:	log Koc: 4.35 Method: OECD Test Guideline 106		
12.5 Resu	ilts of PBT and vPvB a	sse	ssment		
Prod	uct:				
Asse	ssment	:	to be either persi	nixture contains no components considered stent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of	
12.6 Othe	r adverse effects				
Prod	<u>uct:</u>				
Endo tial	crine disrupting poten-	:	ered to have end REACH Article 5	ixture does not contain components consid- ocrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.	
SECTION	N 13: Disposal consi	der	ations		
13.1 Wast	te treatment methods				
Produ	uct	:	•	ordance with local regulations.	

Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Contaminated packaging	 Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN	:	UN 3077
ADR	:	UN 3077
RID	:	UN 3077

according to Regulation (EC) No. 1907/2006



Version 2.6	Revision Date: 09.04.2021		9S Number: 486-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
IMDG			UN 3077	
IATA			UN 3077	
	oper shipping name	•		
ADN		:	ENVIRONMENT N.O.S. (Ezetimibe, Ator	ALLY HAZARDOUS SUBSTANCE, SOLID,
ADR		:		ALLY HAZARDOUS SUBSTANCE, SOLID,
RID		:	ENVIRONMENT N.O.S. (Ezetimibe, Ator	ALLY HAZARDOUS SUBSTANCE, SOLID,
IMDG		:	ENVIRONMENT N.O.S. (Ezetimibe, Ator	ALLY HAZARDOUS SUBSTANCE, SOLID,
ΙΑΤΑ		:	Environmentally (Ezetimibe, Ator	hazardous substance, solid, n.o.s. vastatin)
14.3 Trans	port hazard class(es)			
ADN		:	9	
ADR		:	9	
RID		:	9	
IMDG		:	9	
ΙΑΤΑ		:	9	
14.4 Packi	ng group			
Classi	ng group fication Code d Identification Number	:	III M7 90 9	
Classi Hazar Labels	ng group fication Code d Identification Number s el restriction code	:	III M7 90 9 (-)	
Classi Hazar Labels IMDG	ng group	:	III M7 90 9 III 9	

according to Regulation (EC) No. 1907/2006



Ezetimibe / Atorvastatin Formulation

Versio 2.6	n Revision Date: 09.04.2021		DS Number: 9486-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014		
E	mS Code	:	F-A, S-F			
P ai	TA (Cargo) acking instruction (cargo ircraft) acking instruction (LQ)	:	956 Y956			
	acking group abels	:	III Miscellaneous			
	ATA (Passenger)	•	MISCEIIAIIEOUS			
P ge P	acking instruction (passen- er aircraft) acking instruction (LQ) acking group	:	956 Y956 III			
	abels	:	Miscellaneous			
14.5 E	nvironmental hazards					
	DN nvironmentally hazardous	:	yes			
	DR nvironmentally hazardous	:	yes			
E	ID nvironmentally hazardous	:	yes			
	IDG larine pollutant	:	yes			
	ATA (Passenger) nvironmentally hazardous	:	yes			
	ATA (Cargo) nvironmentally hazardous	:	yes			
14.6 Special precautions for user						

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks

: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII)	:	Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer	:	Not applicable



according to Regulation (EC) No. 1907/2006

Ezetimibe / Atorvastatin Formulation

Version 2.6	Revision Date: 09.04.2021	SDS Number: 26486-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
tants	ulation (EU) 2019/1021 (recast)		
men	ulation (EC) No 649/201 t and the Council conce angerous chemicals		
	eso III: Directive 2012/18 pr-accident hazards invo		n Parliament and of the Council on the control of
maju		iving dangerous sub:	Quantity 1 Quantity 2
E2		ENVIRONMEN HAZARDS	NTAL 200 t 500 t
Othe	er regulations:		
	e note of Directive 94/33 lations, where applicable	•	n of young people at work or stricter national
The	components of this pr	oduct are reported	in the following inventories:
AICS	6	: not determined	d
DSL		: not determined	d
IECS	SC	: not determined	d
	mical safety assessme cal Safety Assessment h		out.

SECTION 16: Other information							
Other information		Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.					
Full text of H-Statements							
H373		May cause damage to organs through prolonged or repeated exposure if swallowed.					
H410		Very toxic to aquatic life with long lasting effects.					
H411	:	Toxic to aquatic life with long lasting effects.					
Full text of other abbreviation	ns						
Aquatic Chronic		Long-term (chronic) aquatic hazard					
STOT RE		Specific target organ toxicity - repeated exposure					
GB EH40		UK. EH40 WEL - Workplace Exposure Limits					
GB EH40 / TWA		Long-term exposure limit (8-hour TWA reference period)					
GB EH40 / STEL	•	Short-term exposure limit (15-minute reference period)					

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentrational Carriage of Dangerous Community Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation; (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELX - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentrational Carriage Agency; ECA - Domestic Substances (Japan); ErCx - Concentrational Carriage Agency; ECA - Domestic Substances (Japan); ErCx - Concentrational Carriage Agency; ECA - Domestic Substances (Japan); ErCx - Concentrational Carriage Agency; ECA - Domestic Substances (Japan); ErCx - Concentrational Carriage Agency; ECA - Domestic Substances (Japan); ErCx - Concentrational Carriage Agency; ECA - Domestic Substances (Japan); ErCx - Concentrational Cariage Agency; ECA - Domestic Substances (Japan); ErCx - Concentr



Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.6	09.04.2021	26486-00016	Date of first issue: 29.10.2014

tration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice: IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS -Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data Sheet	eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/
oneet	by, http://ocha.ou/opa.ou/

Classification of the m	Classification procedure:	
STOT RE 2	H373	Calculation method
Aquatic Chronic 2	H411	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN